Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-1347-42 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment. Applications Reported: The ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis. Applications Tested: This ACT35 (ACT-35) antibody has been pre-titrated and tested by flow cytometric analysis of 3-day PHA-stimulated normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- ACT35 (ACT-35)
- Vial size
- 100 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients.
Theodoraki MN, Laban S, Jackson EK, Lotfi R, Schuler PJ, Brunner C, Hoffmann TK, Whiteside TL, Hofmann L
British journal of cancer 2021 Dec;125(12):1677-1686
British journal of cancer 2021 Dec;125(12):1677-1686
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of 3-day PHA-stimulated normal human peripheral blood cells with Mouse IgG1 kappa Isotype Control APC (Product # 17-4714-81) (blue histogram) or Anti-Human CD134 (OX40) APC (purple histogram). Total viable cells were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Surface values of immune checkpoints on exosomes isolated from plasma of HNSCC patients. Exosomes from n = 17 HNSCC patients obtained at defined time-points were captured using biotinylated CD63-antibodies and stained with fluorochrome-conjugated antibodies against PD-L1 ( a ), CTLA-4 ( b ), OX40 ( c ) and OX40-L ( d ). Surface values as determined by on-bead flow cytometry are shown as RFI compared to an appropriate isotype control. Results are plotted as box-and-whisker blots representing the median value, the 25th and 75th quartiles and the range. Wilcoxon related samples tests were applied to each compare pre-OP, post-OP, end (C)RT and follow-up. Mann-Whitney test was applied to compare recurrence with follow-up. * or # and ** or ## correspond to p